156. レット症候群 Rett syndrome Clinical trials / Disease details
臨床試験数 : 40 / 薬物数 : 53 - (DrugBank : 19) / 標的遺伝子数 : 77 - 標的パスウェイ数 : 113
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01777542 (ClinicalTrials.gov) | January 2013 | 23/1/2013 | Treatment of Rett Syndrome With Recombinant Human IGF-1 | Pharmacological Treatment of Rett Syndrome by Stimulation of Synaptic Maturation With Recombinant Human IGF-1(Mecasermin [rDNA] Injection) | Rett Syndrome | Drug: Recombinant Human Insulin Growth Factor 1 (rhIGF-1);Drug: Placebo | Boston Children's Hospital | International Rett Syndrome Foundation | Completed | 2 Years | 10 Years | Female | 30 | Phase 2 | United States |